1 / 19

Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness

Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness. Warfarin-Related Costs in Denmark. NICE Guidelines: Reassessing Anticoagulation. Warfarin and the Cost of Bleeding. Warfarin-Related Intracerebral Bleeding and Ischemic Stroke in Germany.

ivor-cervantes
Download Presentation

Stroke Prevention With the NOACs— From Guidelines to Cost-Effectiveness

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stroke Prevention With the NOACs—From Guidelines to Cost-Effectiveness

  2. Warfarin-Related Costs in Denmark

  3. NICE Guidelines: Reassessing Anticoagulation

  4. Warfarin and the Cost of Bleeding

  5. Warfarin-Related Intracerebral Bleeding and Ischemic Stroke in Germany

  6. Non-Vitamin K Oral Anticoagulants:Stroke Outcomes vs Warfarin

  7. Optimal Stroke Prevention in AF: Populations in Need of Treatment

  8. Patient and Physician Attitudes on Stroke Prevention and Bleeding in AF

  9. Guidelines for the Management of AF

  10. CHA2DS2-VASc: Risk Factors for Stroke

  11. Stroke Prevention in AF: CHA2DS2-VASc

  12. 2012 ESC AF Management Guidelines: Using CHA2DS2-VASc

  13. Stroke Risk Reduction in AF With Anticoagulants and Aspirin

  14. Mean TTR in SPAF Patients on Warfarin: Country Variability in the RE-LY Trial*

  15. Warfarin Median TTR in the NOAC Trials

  16. Warfarin 30-Day Stroke Rate: UK Clinical Practice Research Datalink Analysis

  17. FDA Drug Safety Communication on Dabigatran: Outcomes vs Warfarin

  18. Danish National Registry: 4978 Patients With AF Treated With Dabigatran

  19. Thank you for participating in this activity.

More Related